Towards Healthcare Research & Consulting
CAR T-Cell Therapy for Solid Tumors Market
Updated Date: 08 July 2026   |   Report Code: 6999

CAR T-Cell Therapy for Solid Tumors Market Size, Share & Growth Forecast 2026–2035

According to Rohan Patil, who specializes in healthcare research, pharmaceuticals, and therapeutic areas with 5+ years of experience in market research and industry analysis, extensive research indicates strong growth opportunities in the CAR T-cell therapy for solid tumors market. The CAR T-cell therapy for solid tumors market size was estimated at USD 1.42 billion in 2025 and is predicted to increase from USD 1.83 billion in 2026 to approximately USD 17.98 billion by 2035, expanding at a CAGR of 28.9% from 2026 to 2035. His analysis highlights vast growth in the patient population and the need for durable treatments, with breakthroughs in gene editing & next-generation CAR design. The research also examines the competitive strategies of key industry participants, including CARsgen Therapeutics, Autolus Therapeutics, Novartis, Adaptimmune, Gilead Sciences (Kite), & Bristol Myers Squibb (BMS), shaping the future of CAR T-cell therapy for solid tumors in the global market.

Last Updated : 08 July 2026 Category: Therapeutic Area Insight Code: 6999 Format: PDF / PPT / Excel

Content

Chapter 1: Introduction

  • Market Definition & Taxonomy
  • Research Objectives
  • Market Scope & Assumptions
  • Study Timeline (Historical, Base Year, Forecast Period)
  • Key Stakeholders Covered

Chapter 2: Research Methodology

  • Research Framework Overview
  • Market Size Estimation Methodology
    • Bottom-Up Approach
    • Top-Down Approach
  • Forecasting Model
    • Dependent Variables
    • Independent Variables
    • Key Assumptions & Weightages
  • Primary Research Insights
  • Secondary Data Sources
  • Data Validation & Triangulation

Chapter 3: Executive Summary

  • Global & Regional Overview (Value, CAGR)
  • Epidemiology Snapshot
  • Segmental Overview
  • Competition Key Snippets
  • Strategic Takeaways

Chapter 4: Market Catalysts, Constraints & Growth Levers

  • Market Dynamics
  • Market Drivers/Catalysts
    • Driver 1
    • Driver 2
  • Market Restraints
    • Restraint 1
    • Restraint 2
  • Market Opportunities
    • Opportunity 1
    • Opportunity 2
  • Market Trends
    • Trend 1
    • Trend 2
  • Impact Assessment of Drivers, Restraints, Opportunities & Trends (High, Mid, & Low)

Chapter 5: Value Added Intelligence

  • Porter’s Five Forces Analysis
    • Bargaining Power of Suppliers: Low/Moderate/High
    • Bargaining Power of Buyers: Low/Moderate/High
    • Threat of New Entrants: Low/Moderate/High
    • Threat of Substitute: Low/Moderate/High
    • Competitive Rivalry: Low/Moderate/High
  • PESTEL Analysis
  • Ecosystem Analysis
  • Mapping of Key Players
  • Value Chain Analysis
  • Margin Analysis Across Value Chain
  • Macro & Micro Factors Impacting Market
  • Market Potential Evaluation, By Region
  • Epidemiology & Patient Pool Analysis
    • Disease Incidence & Prevalence
    • Target Patient Pool
      • Diagnosed Population
      • Service-Seeking Population
    • Patient Flow & Utilization Analysis
      • Patient Footfall
      • Admission Rates
      • Procedure Volume
    • Healthcare Infrastructure Analysis
      • Number of Facilities
        • Hospitals
        • Clinics
        • Diagnostic Centers
        • ASCs
      • Bed Capacity
        • Total Beds
        • ICU Beds
      • Facility Distribution
    • Operational Metrics Analysis
      • Bed Occupancy Rate (%)
      • Average Length of Stay (ALOS)
    • Service Pricing & Revenue Model
      • Pricing Analysis
        • Cost per Procedure
        • Cost per Consultation
        • Cost per Diagnostic Test
      • Revenue Streams
        • Inpatient Services
        • Outpatient Services
        • Ancillary Services
      • Workforce & Staffing Analysis
        • Healthcare Workforce
          • Physicians
          • Nurses
          • Technicians
        • Staff-to-Patient Ratios
        • Skill Gap Analysis
        • Labor Cost Structure
      • Scenario Analysis (Base / Optimistic / Pessimistic)
      • Risk Assessment & Sensitivity Analysis
      • Opportunity Analysis, By Region
      • Regulatory Analysis
      • Sustainability & ESG Insights
      • Business Models
      • Investment & Funding Landscape
      • Key Conferences and Events

Chapter 7: Segmental & Regional Analysis

  • CAR T-Cell Therapy for Solid Tumors Market Analysis,By Target Antigen
    • Market Size, Forecast & CAGR,By Target Antigen, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • CAR T-Cell Therapy for Solid Tumors Market Analysis, By Tumor Type
    • Market Size, Forecast & CAGR, By Target Antigen, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • CAR T-Cell Therapy for Solid Tumors Market Analysis, By CAR T-Cell Generation
    • Market Size, Forecast & CAGR, By Target Antigen, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • CAR T-Cell Therapy for Solid Tumors Market Analysis, By Therapy Type
    • Market Size, Forecast & CAGR, By Target Antigen, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • CAR T-Cell Therapy for Solid Tumors Market Analysis, By Delivery Route
    • Market Size, Forecast & CAGR, By Target Antigen, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • CAR T-Cell Therapy for Solid Tumors Market Analysis, By End User
    • Market Size, Forecast & CAGR, By Target Antigen, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • CAR T-Cell Therapy for Solid Tumors Market Analysis, By Development Stage
    • Market Size, Forecast & CAGR, By Target Antigen, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • CAR T-Cell Therapy for Solid Tumors Market Analysis, By Region
    • Market Size, Forecast & CAGR, By Target Antigen, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • North America CAR T-Cell Therapy for Solid Tumors Market Analysis
  • North America CAR T-Cell Therapy for Solid Tumors Market Analysis,By Target Antigen, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • North America CAR T-Cell Therapy for Solid Tumors Market Analysis, By Tumor Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • North America CAR T-Cell Therapy for Solid Tumors Market Analysis, By CAR T-Cell Generation, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • North America CAR T-Cell Therapy for Solid Tumors Market Analysis, By Therapy Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • North America CAR T-Cell Therapy for Solid Tumors Market Analysis, By Delivery Route, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • North America CAR T-Cell Therapy for Solid Tumors Market Analysis, By End User, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • North America CAR T-Cell Therapy for Solid Tumors Market Analysis, By Development Stage, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • North America CAR T-Cell Therapy for Solid Tumors Market Analysis, By Country, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
      • U.S. CAR T-Cell Therapy for Solid Tumors Market Analysis
    • U.S. CAR T-Cell Therapy for Solid Tumors Market Analysis, By Target Antigen, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
    • U.S. CAR T-Cell Therapy for Solid Tumors Market Analysis, By Tumor Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
    • U.S. CAR T-Cell Therapy for Solid Tumors Market Analysis, By CAR T-Cell Generation, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
    • U.S. CAR T-Cell Therapy for Solid Tumors Market Analysis, By Therapy Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
    • U.S. CAR T-Cell Therapy for Solid Tumors Market Analysis, By Delivery Route, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
    • U.S. CAR T-Cell Therapy for Solid Tumors Market Analysis, By End User, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
    • U.S. CAR T-Cell Therapy for Solid Tumors Market Analysis, By Development Stage, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis

Similar Analysis will be given for each country and each region

  • Canada
  • Mexico
  • Rest of North America

Europe

  • Western Europe
  • Germany
  • Italy
  • France
  • Spain
  • UK
  • Netherlands
  • Switzerland
  • Nordic Countries
  • Rest of Western Europe
  • Eastern Europe
  • Austria
  • Russia & Belarus
  • Poland
  • Türkiye
  • Rest of Eastern Europe

Asia Pacific

  • China
  • Taiwan
  • India
  • Japan
  • Vietnam
  • Australia and New Zealand
  • ASEAN Countries
  • South Korea
  • Rest of APAC

South America

  • Brazil
  • Argentina
  • Rest of South America

Middle East and Africa (MEA)

  • GCC Countries
  • South Africa
  • Egypt
  • Rest of MEA

Chapter 6: Competitive Insights

  • Competitive Analysis
    • Company Evaluation Matrix
      • Major Players
      • Mid-Sized Companies
      • Emerging Players/Start-Ups
    • Global Market Share Analysis, By Region, 2025 (%)
    • Key Player Positioning
    • Competitive Benchmarking
      • By Target Antigen
      • By Tumor Type
      • By CAR T-Cell Generation
      • By Therapy Type
      • By Delivery Route
      • By End User
      • By Development Stage
    • Strategies of Key Players
    • Insight From the Horse’s Mouth
  • Company Profiles
    • CARsgen Therapeutics
      • Company Name
      • Company Headquarters
      • Management Overview
        • Key C-Suite Executives
          • CEO
          • MD
          • Others
        • Employee Count
        • Business Strategy
          • Key Investments Made
          • Future Plans
          • R&D & Innovation Capabilities
          • Recent Developments
            • New Product Launch
            • Merger & Acquisitions
            • Partnerships & Collaborations
            • Market Expansion
            • Others
          • Service Portfolio
          • Facility Network
            • Number of Facilities
            • Bed Capacity
            • Facility Distribution
            • Expansion Pipeline
          • Key Financials (2022-2025)
            • Revenue By Segment
            • Revenue By Service
            • Revenue By Geography
            • Financial Matrix (Gross Profit Margins, Net Margins, etc.)
          • Key Clients
            • Client Company Name
            • Key Contact Person
            • Contact Details
          • Regulatory & Certification Expertise
          • SWOT Analysis
    • BioNTech
    • Autolus Therapeutics
    • Gilead Sciences (Kite Pharma)
    • Novartis
    • Legend Biotech
    • Bristol Myers Squibb (BMS)
    • Atara Biotherapeutics
    • Noile-Immune Biotech
    • Immatics

FAQ's

Answer : The global CAR T-cell therapy for solid tumors market is expanding in 2026 due to accelerating innovations in ultra-sensitive receptors to detect low-level antigens, armored CAR-Ts to combat the immunosuppressive tumor microenvironment (TME), and multiplexed/modular CARs.

Answer : The intravenous (IV) route led the market in 2025 due to its standard administration method, high clinical familiarity, & broadly support for multi-center trials.

Answer : US FDA, CDSCO, EMA, CDC, NIH, NCI, PMC, Clinical Trials.gov, PIB, ACTREC, CMS, MedlinePlus.gov, etc.

Meet the Team

Rohan Patil is a seasoned market research professional with over 5+ years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.

Learn more about Rohan Patil

Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.

Learn more about Aditi Shivarkar